August 9, 2024 07:22 AM EDT
Deals
China
Pharma

Mer­ck pays $700M for clin­i­cal-stage CD3xCD19 bis­pe­cif­ic an­ti­body

Kyle LaHucik

Senior Reporter

Mer­ck is mak­ing its fourth ac­qui­si­tion of the year, this time buy­ing a sin­gle as­set from a Shang­hai-based can­cer drug de­vel­op­er.

The New Jer­sey phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: Bain scoops up $3B for fourth life sci­ences fund af­ter hand­ful of M&A deals

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Roche's dual GLP-1/GIP re­sults show promis­ing weight loss, but al­so high rates of vom­it­ing

Up­dat­ed: Virid­i­an re­veals first Phase 3 eye dis­ease da­ta in bid to com­pete with Te­pez­za

A service from the Financial Times